ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1341	National Cancer Institute	Html	en	Smokeless Tobacco and Cancer	A fact sheet about the health risks associated with the use of smokeless tobacco.	tobacco cut size 0.465919 NCI smoking cessation 0.353151 safe level 0.345736 oral tobacco 0.470575 nicotine addiction 0.363201 Human Services 0.340767 Health State-of-the-Science conference 0.343313 U.S. Department 0.340786 tobacco-specific nitrosamines 0.373338 tobacco fertilizer 0.451995 advisory committee 0.346137 powdered tobacco 0.462627 Health Organization International 0.342988 oral cancer 0.332186 National Institutes 0.343448 Watson C. Surveillance 0.3381 Tobacco Control Monograph 0.451686 moist snuff 0.436686 precancerous white patches 0.344838 International Agency 0.339252 NCI’s Smoking 0.334129 Tobacco Research 0.437462 NCI fact sheet 0.385333 lower lip 0.34967 esophageal cancer 0.332063	nicotine stays 0.353085 Yes. All tobacco 0.450832 National Cancer Institute 0.373261 LiveHelp online chat 0.341688 American snuff 0.346643 polynuclear aromatic hydrocarbons 0.347124 Eastern time 0.340428 spitting tobacco 0.470917 online text chat 0.340605 polycyclic aromatic hydrocarbons 0.346589 smokeless tobacco products 0.615213 smokeless tobacco cause 0.576883 Nicotine content 0.350271 un-ionized nicotine 0.348074 Surgeon General 0.344959 smokeless tobacco 0.995709 Yes. Smokeless tobacco 0.55885 dry snuff 0.363969 noncancerous oral conditions 0.343638 NIH State-of-the-Science Panel 0.338818 tobacco cause cancer 0.483342 smoking cessation counselor 0.38611 tobacco juices 0.469352 harmful chemicals 0.350583	CLICK HERE
1394	National Cancer Institute	Html	en	Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors).	patient selection factors 0.438228 tumor cell types 0.413939 functional tumors 0.556939 slow-growing tumors 0.428195 pituitary tumors 0.418826 functional pancreatic neuroendocrine 0.426256 islet cell tumors 0.811481 preoperative dual-phase thin-section 0.348132 bone metastases 0.398217 islet cell cancers 0.399777 distinctive metabolic effects 0.341484 secondary endocrine tumors 0.452606 liver metastases 0.990586 unresectable liver metastases 0.497768 endocrine pancreas glands 0.386 metastatic disease 0.427564 sporadic islet cell 0.397131 resectable liver metastases 0.506505 venous sampling 0.390094 surgical resection series 0.389796 visible liver metastases 0.615044 liver neuroendocrine metastases 0.512043 individual tumors 0.388972 progressive pancreatic NETs 0.411807 clinical manifestations 0.349816	percutaneous alcohol ablation 0.339566 antihormonal pharmacologic therapy 0.339279 conventional imaging techniques 0.33881 radiofrequency ablation 0.342021 pancreatic resection 0.466639 pancreatic islets 0.36916 ulcer-producing Zollinger-Ellison syndrome 0.354188 somatostatin-receptor scintigraphy 0.356211 slow-growing metastatic islet 0.423125 pancreatic NETs 0.575547 technically demanding tests 0.350314 multiple endocrine neoplasia 0.362304 retrospective case series 0.340498 hormonally functional tumors 0.47568 tumor suppressor gene 0.392672 pancreatic islet cell 0.465855 overall tumor burden 0.363718 grossly visible liver 0.505977 MEN-1 syndrome 0.346786 pancreatic neuroendocrine tumors 0.701933 liver resection 0.37949 arterial stimulation 0.345171 common exocrine adenocarcinomas 0.348715 preoperative localization studies 0.4603	CLICK HERE
1537	National Cancer Institute	Html	en	Newcastle Disease Virus (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of Newcastle disease virus (NDV) as a treatment for people with cancer.	metastatic tumor cells 0.405592 tumor cell lines 0.391976 human cancer cells 0.50054 genetically engineered NDV 0.389911 NDV oncolysates 0.413317 autologous tumor vaccine 0.41773 infected cells 0.416882 historical control subjects 0.398257 irradiated ESb cells 0.39152 Cancer Res 0.395898 disease virus therapy 0.398313 virus-modified tumor cells 0.412589 virus-modified autologous tumor 0.394368 autologous tumor cell 0.439505 patients 0.465722 Natl Cancer Inst 0.401926 human tumor cells 0.440276 lytic strains 0.409693 normal human cells 0.424643 cell vaccines 0.393769 et al. 0.391296 autologous tumor cells 0.542424 colorectal cancer patients 0.390231 cancer cells 0.51627 newcastle disease virus 0.925041	primary tumor cells 0.39623 PUBMED Abstract 0.426283 disease virus vaccine 0.404352 uninfected cancer cells 0.394475 tumor cells 0.60365 tumor cell vaccine 0.404276 progeny virus particles 0.393227 NDV 0.533791 Abstract 0.460011 human immune cells 0.389104 autologous cells 0.393227 NDV genetic material 0.390979 nonlytic NDV strains 0.407173 NDV-infected cancer cells 0.395154 malignant melanoma patients 0.394264 Human tumor cell 0.388361 renal cell carcinoma 0.423539 cells 0.622446 main NDV proteins 0.390649 ESb cells 0.400925 NDV strains 0.410203 regional lymph nodes 0.425639 cancer 0.567906 irradiated tumor cells 0.398885	CLICK HERE
1696	National Cancer Institute	Html	en	Topics in Integrative, Alternative, and Complementary Therapies (PDQ®)–Health Professional Version	Expert-reviewed information summary that contains information on integrative, complementary, and/or alternative therapies for people with cancer.	cancer treatment 0.500109 standard treatments 0.546145 National Health Interview 0.49394 randomized controlled trials 0.478599 good manufacturing processes 0.485786 Cancer Complementary 0.466196 blood cell count 0.487384 NCI Fact Sheets 0.492301 concomitantly administered drugs 0.486833 depression management 0.497623 cancer information summary 0.503433 potentially active ingredients 0.480985 PDQ summaries 0.45939 St. John 0.975444 cancer patients 0.494368 NCI Fact 0.496884 wort 0.678406 effects 0.47211 complementary therapies 0.460635 cancer survivors 0.459401 PDQ summary section 0.501629 human immunodeficiency virus 0.480593 various metabolic enzymes 0.481932 major active constituents 0.486518 commonly treated symptoms 0.485606	Chinese medical therapies 0.495937 antidepressant therapy 0.478022 deep breathing exercises. 0.492057 Complementary medicine 0.467053 CAM therapies 0.48574 specific PDQ summary 0.501712 dietary supplements 0.496339 systemic concentrations 0.461386 alternative medicine 0.659692 herbal agent 0.488319 natural killer cell 0.486571 lower concentrations 0.45956 traditional Chinese medicine 0.494167 clinically important effect 0.485748 monoamine oxidase inhibitor 0.490216 PDQ summary 0.540549 randomized controlled trials. 0.478417 popular herbal agent 0.484348 NCI Fact Sheet 0.49194 major depressive disorder 0.543366 Alternative Medicine website 0.499408 sufficient concentrations 0.46476 milder depression 0.458918 cancer 0.510149	CLICK HERE
1985	National Cancer Institute	Html	es	Descripción del tratamiento de tumores de encéfalo y de médula espinal infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de tumores de encéfalo infantiles.	espinal infantiles.ampliar punción 0.671368 Organización Mundial 0.330213 células madre 0.838888 efectos secundarios meses 0.514746 siguientes aspectos 0.364078 vía oral 0.337627 encéfalo benignos 0.752955 PDQ Descripción 0.372391 efectos tardíos 0.660507 PDQ correspondiente 0.464116 tumor subtipo 0.432726 PDQ Efectos tardíos 0.450037 cáncer.ampliar aspiración 0.351047 Astrocitoma pilomixoide 0.336263 líquido cefalorraquídeo 0.817195 National Cancer Institute 0.340319 siguientes riesgos 0.328861	Instituto Nacional 0.370517 PDQ Tratamiento 0.975349 riesgo promedio 0.357023 presente sección 0.332468 siguientes signos 0.392336 nuevos tipos 0.34964 siguientes factores 0.362333 sistema nervioso central 0.653419 Physician Data Query 0.447911 gliomas astroblastoma 0.333341 pdq correspondiente tipo 0.412457 alto astrocitoma 0.3322 panel derecho 0.358602 espinal infantiles recién 0.572263 siguientes pruebas 0.390652 siguientes sumarios 0.353304 siguientes trastornos 0.347907	CLICK HERE
1999	National Cancer Institute	Html	es	Tratamiento de los astrocitomas infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los astrocitomas infantiles.	siguientes procedimientos 0.509449 células madre 0.756546 siguientes aspectos 0.541249 efectos secundarios meses 0.505608 sustancia llamada fcev 0.432048 prueba mib-1 0.42502 vía oral 0.416944 encéfalo benignos 0.476825 único tratamiento 0.445679 proteína cinasa.Los inhibidores 0.434623 glioma coroideo 0.430143 escasas ocasiones 0.429534 células t 0.452739 efectos tardíos 0.580441 estrella llamadas 0.429847 PDQ Efectos tardíos 0.459317 National Cancer Institute 0.412326 tumores benignos 0.512758 siguientes riesgos 0.412382	alto recién 0.437854 Instituto Nacional 0.422716 PDQ Tratamiento 0.437378 determinados cambios 0.429353 neurofibromatosis tipo 0.592389 tanta cantidad 0.426418 presente sección 0.412644 nuevos tipos 0.4212 siguientes casos 0.43033 sistema nervioso central 0.991625 Physician Data Query 0.447246 siguientes partes 0.443422 cuánto tumor 0.508299 cuerpo.ampliar derivación 0.416932 células cancerosas.Hay 0.455449 panel derecho 0.460499 siguientes sumarios 0.465245 vasos sanguíneos 0.616892	CLICK HERE
2021	National Cancer Institute	Html	es	Prevención del cáncer de cuello uterino (PDQ®)–Versión para pacientes	Información revisada por expertos sobre los factores que pueden aumentar el riesgo de cáncer de cuello uterino y los enfoques que podrían ayudar a la prevención de esta enfermedad.	Visuals Online 0.544747 PDQ Exámenes 0.729141 Internet NCI 0.599334 siguientes factores 0.942852 voluntarios sanos 0.571782 Physician Data Query 0.821847 Estados Unidos 0.732136 suficiente ejercicio 0.608117	prevención revisa 0.577919 PDQ Prevención 0.648162 cuánto tiempo 0.58363 National Cancer Institute 0.579131 invasivo aumenta 0.607513 siguientes riesgos 0.566231 siguientes sumarios 0.745167 Instituto Nacional 0.648132	CLICK HERE
2050	National Cancer Institute	Html	es	Análisis del antígeno prostático específico (PSA)	Hoja informativa sobre la prueba del antígeno prostático específico (PSA) y los exámenes selectivos de detección para el cáncer de próstata, y clarifica los beneficios y limitaciones de dicha prueba.	posibles complicaciones 0.529476 United States Preventive 0.549836 hiperplasia prostática benigna 0.569875 fusión génica tmprss2-erg 0.5485 estudio plco 0.535774 PLCO trials 0.538088 eréctil o incontinencia 0.532144 médico quizás 0.54755 ng per milliliter 0.54786 concentration-based assay 0.526257 Pauler DK 0.526835 structure-based isopsa assay 0.54715 estudio clínico plco 0.561758 tanta lentitud 0.531594 posibles perjuicios 0.59922 riesgos y beneficios 0.531533 Servicios Preventivos 0.526931 European Randomised Study 0.54659 hiperplasia benigna 0.602949 Preventive Health Services 0.541802 llamadas isoformas 0.529743 Screening Draft Recommendations 0.555159	Hugosson J 0.571924 espectro de  isoformas 0.553214 Instituto Nacional 0.525806 próstata en asociación 0.528933 PSA quizás 0.924082 posibles efectos 0.527227 Internal Medicine 0.527548 Services Task Force 0.63375 among men with 0.545229 estados benignos 0.530298 agrandamiento benigno 0.537792 PubMed Abstract 0.784346 prostate cancer 0.975142 estadio inicial quizás 0.562336 obstante exámenes 0.563732 New England Journal 0.630867 Goodman PJ 0.525307 de 1 muerte 0.528041 Roobol MJ 0.576631 pequeños tumores 0.530536 Heijnsdijk EAM 0.527351 Hafron JM 0.526062	CLICK HERE
15632	National Cancer Institute	Html	null	NCI Grant Application Development, Submission, and Award	Learn how the six-step process of the NCI grants process works— from application development, to peer review, to post-award administration.			CLICK HERE
16844	National Cancer Institute	Html	en	Ohio State University and University of Kentucky — Optimizing RNA Nanoparticle's Size and Shape for Enhancing Cancer Targeting and Treatment	A systematic characterization of RNA nanoparticle behavior, in vitro and in vivo, to optimize its cellular delivery to triple negative breast cancer (TNBC).	optimized therapeutic systems 0.528757 varying shapes 0.305417 moieties 0.241586 endosomal escape 0.300775 RNA nanoparticle behavior 0.817424 optimum shape 0.346242 project team 0.300326 vivo delivery 0.345174 overall goal 0.318652 therapeutic components 0.373072 Jianhua Yu 0.345836 tumor regression 0.318722 Enhancing Cancer Targeting 0.687284 William Carson 0.342459 internalization/intracellular trafficking 0.315312 efficient therapeutic delivery 0.542327 surgical oncology 0.297773	delivery systems 0.312116 pharmacokinetic profiles 0.331727 Daniel Pack 0.340086 Ohio State University 0.5489 nanoparticle size 0.433341 gene therapy 0.299174 RNA nanoparticles 0.513535 negative breast cancer 0.501323 facile chemical processing 0.476016 rna nanoparticle 0.954079 Principal Investigators 0.353961 Peixuan Guo 0.400645 favorable biodistribution 0.529957 molecular / cell 0.296003 cancer immunotherapy 0.325509 systematic studies 0.315425 systematic characterization 0.33975	CLICK HERE